Over The Counter 24 May 2022: US OTC Monograph Reform And A 'Faster Moving FDA’ With CHPA’s Barbara Kochanowski and David Spangler
Executive Summary
In this episode, HBW Insight speaks to Barbara Kochanowski and David Spangler of the US Consumer Healthcare Products Association about OTC monograph reform. The OTC monograph program was reimagined as a part of the 2020 CARES act passed in the early stages of the pandemic. While the changes were designed to streamline and modernize the program, results have been slow with the FDA's attention focused on tackling COVID-19. But as the agency hires more staff, Spangler says he expects to see a "faster moving FDA" in the next three years. Spangler and Kochanowski also discuss the efficacy of the monograph reforms and how CHPA has helped educate its members about the changes.
You may also be interested in...
After 10 Years, US FDA ‘Additional Conditions’ Proposed Rule Offers ‘Novel Switch’ Pathway
Publication of "ACNU" proposed rule wasn’t reached in straight line and featured coining another term with more of a regulatory sound, “NSURE,” and detours on explaining where the agency wouldn’t steer OTC drug manufacturing and marketing.
USPSTF Doesn’t See Forest Of VMS Benefits For Trees Of Reducing Cancer, Heart Disease Risks
US Preventative Services Task Force concludes evidence doesn't support recommending VMS use to prevent cancer or cardiovascular disease. Trade groups and a natural medicine expert say task force's focus is narrow and its recommendation misleading.
CHPA Adds Pavlick, Miller In Director Posts
Larisa Pavlick joins senior director of quality assurance and technical affairs, and Kirby Miller as director of federal government affairs.